Please login to the form below

Not currently logged in
Email:
Password:

Research and Development

This page shows the latest Research and Development news and features for those working in and with pharma, biotech and healthcare.

UCB signs research deal with King’s College London

UCB signs research deal with King’s College London

We are therefore thrilled to be able to announce this new collaboration with King’s, which we believe will further augment our collective research and development capabilities in the pursuit of ... our world class expertise in translational research

Latest news

  • AZ says dropping MedImmune will help ‘streamline’ its R&D AZ says dropping MedImmune will help ‘streamline’ its R&D

    to further integrate research and development and accelerate decision-making and the launches of new medicines, consolidating what we believe is already one of the most exciting and productive pipelines in ... returns on investment, while the blurring of

  • Skills shortage and Brexit will hit R&D, warns UK pharma Skills shortage and Brexit will hit R&D, warns UK pharma

    Skill shortages and Brexit seen as greatest threat. The UK is in danger of losing its world-leading research and development status, the Association of the British Pharmaceutical Industry (ABPI) has ... These skills are crucial for leading research and

  • Horizon taps academic partner to boost gene editing platform Horizon taps academic partner to boost gene editing platform

    Dr. David Kimball, Interim Senior Vice President for Research and Economic Development at Rutgers University, added: “Gene editing technology has truly revolutionised how scientists think about their search for better options ... Horizon has also

  • AstraZeneca unveils reorg, hires controversial José Baselga as cancer chief AstraZeneca unveils reorg, hires controversial José Baselga as cancer chief

    Mene Pangalos will be the leader of a new unified Research and Development unit for BioPharmaceuticals, ending the split between MedImmune biologics research and AstraZeneca’s small molecule research division. ... Pangalos was previously head of AZ’s

  • Pharma’s R&D productivity sinks to a new low Pharma’s R&D productivity sinks to a new low

    Consultants Deloitte have just released their annual update on productivity, and the figures are grim: projected returns on investment in research and development for the top 12 pharmaceutical companies have fallen ... The research by Deloitte’s Centre

More from news
Approximately 10 fully matching, plus 626 partially matching documents found.

Latest Intelligence

  • Unlocking the potential of science and technology in the UK Unlocking the potential of science and technology in the UK

    The Industrial Strategy set out the laudable objective of the government working with industry to boost spending on research and development to 2.4% of GDP by 2027. ... Ziylo, based at the Unit DX incubator unit in Bristol, received various forms of

  • The handover: Pfizer reshapes itself for a new era The handover: Pfizer reshapes itself for a new era

    Current global president, worldwide research and development and medical, Mikael Dolsten, will also become chief medical officer. ... John Young, group president and chief business officer, will also assume new responsibilities, which will see him focus

  • Redefining communications excellence Redefining communications excellence

    These research efforts are guided by more data than ever but there are downsides to abundance, particularly when designing disease-specific campaigns that target patients and the general public. ... Measuring success. Audience research, message

  • AstraZeneca: building a new ‘open innovation’ pharma company AstraZeneca: building a new ‘open innovation’ pharma company

    AstraZeneca’s global HQ and Research &Development Centre will house approximately 2, 000 employees, and has been designed specifically to encourage interdisciplinary working with scientists engaged on small molecules, large molecules ... This physical

  • China: AstraZeneca’s new engine for growth and innovation China: AstraZeneca’s new engine for growth and innovation

    with the State Development Investment Corporation (SDIC) to set up Dizal Pharma, a joint venture dedicated to the research and development of new medicines. ... Growing confidence in China as an R&D centre. While some companies have pared back their

More from intelligence
Approximately 0 fully matching, plus 82 partially matching documents found.

Latest appointments

  • New hires at Ferring, Flexion and Immunocore New hires at Ferring, Flexion and Immunocore

    I am excited and honoured to be charged with driving Immunocore’s research and development efforts forward.”. ... His appointment as Head of R&D strengthens Immunocore's leadership team and supports us as we advance our growing pipeline of TCR

  • Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO

    Under Bahija’s leadership, MedImmune significantly boosted its pipeline, expanding from 40 to more than 130 molecules in research and development targeting cancer; respiratory, inflammation, and autoimmunity; cardiovascular, renal and metabolic;

  • New hires at Mundipharma, Sinclair Pharma and Relay Therapeutics New hires at Mundipharma, Sinclair Pharma and Relay Therapeutics

    Latest movers in pharma. Mundipharma hires new SVP business development and strategic partnerships. ... We welcome Mary and Mahesh to Relay Therapeutics, both key additions to our senior R&D leadership team,” said Don Bergstrom, head of research and

  • Pharma industry appointments Pharma industry appointments

    Meanwhile, Silence Therapeutics has also bolstered its leadership team with the addition of Richard Jenkins, who joins the group following 28 years’ experience in clinical development and drug discovery. ... He joins Concept from Eurofins, where he was

  • Axovant poaches Allergan’s and Teva’s chief medical and science officers Axovant poaches Allergan’s and Teva’s chief medical and science officers

    Gavin Corcoran and Michael Hayden join the biopharma. Clinical stage biopharmaceutical group Axovant has appointed Gavin Corcoran as its new executive vice president of research and development. ... Prior to his time at Teva as its president of global

More from appointments
Approximately 0 fully matching, plus 162 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 2 fully matching, plus 72 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

The importance of co-creation with patients
Overcoming the barriers...
Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics